Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite artificial intelligence’s growing role in drug research, a fully AI-generated molecule has yet to advance from discovery all the way through clinical development. A novel molecule may eventually meet that goal, but some industry observers say it’s too early to focus on winning a race that has many twists and turns yet to come.
Exscientia plc (NASDAQ:EXAI – Get Free Report) fell 3.3% during mid-day trading on Friday . The stock traded as low as $5.47 and last traded at $5.63. 106,208 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 431,977 shares. The stock had previously closed at $5.82. Analyst Upgrades […]
Exscientia plc (NASDAQ:EXAI – Get Free Report)’s share price traded down 4.2% during mid-day trading on Monday . The company traded as low as $5.93 and last traded at $5.94. 55,902 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 433,195 shares. The stock had previously closed at […]
Exscientia plc (NASDAQ:EXAI – Get Free Report)’s stock price traded down 4.4% during trading on Monday . The stock traded as low as $5.00 and last traded at $5.03. 52,105 shares were traded during trading, a decline of 88% from the average session volume of 430,774 shares. The stock had previously closed at $5.26. Wall […]
Prof Andrew Hopkins' company uses AI for the discovery and creation of medicine.